Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins.
- 13 September 1994
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 91 (19), 8807-8811
- https://doi.org/10.1073/pnas.91.19.8807
Abstract
The extended interaction of aldoses with proteins or lipids results in nonenzymatic glycation and oxidation, ultimately forming AGEs, the presence of which in the plasma and vessel wall is associated with diabetic vascular complications. We show here that AGE albumin in the intravascular space interacts with the vessel wall via binding to an integral membrane protein, receptor for AGE (RAGE), a member of the immunoglobulin superfamily, resulting in clearance from the plasma and induction of interleukin 6 mRNA. Intravenously infused 125I-AGE albumin showed a rapid phase of plasma clearance with deposition in several organs. Rapid removal of 125I-AGE albumin from the plasma was prevented by administration of a soluble, truncated form of RAGE, which blocked binding of 125I-labeled AGE albumin to cultured endothelial cells and mononuclear phagocytes, as well as by pretreatment with anti-RAGE IgG. Ultrastructural studies with AGE albumin-colloidal gold conjugates perfused in situ showed that in murine coronary vasculature this probe was taken up by endothelial plasmalemmal vesicles followed by transport either to the abluminal surface or by accumulation in intracellular vesicular structures reminiscent of endosomes and lysosomes. Consequences of AGE-RAGE interaction included induction of interleukin 6 mRNA expression in mice. These data indicate that RAGE mediates the interaction of AGEs with the vessel wall, both for removal of these glycated proteins from the plasma and for changes in gene expression.Keywords
This publication has 36 references indexed in Scilit:
- Hyperfibrinogenemia: An important risk factor for vascular complications in diabetesDiabetes Care, 1992
- Variable region cDNA sequences of three mouse monoclonal anti-idiotypic antibodies specific for anti-α(1→6)dextrans with groove- or cavity-type combining sitesMolecular Immunology, 1992
- Glucose and diabetic vascular disease 1The FASEB Journal, 1992
- Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface.Journal of Biological Chemistry, 1992
- Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins.Journal of Biological Chemistry, 1992
- Use of an anti-low density lipoprotein receptor antibody to quantify the role of the LDL receptor in the removal of chylomicron remnants in the mouse in vivo.Journal of Clinical Investigation, 1991
- Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins.The Journal of Experimental Medicine, 1991
- Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivoJournal of Biological Chemistry, 1991
- Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetesBiochemical and Biophysical Research Communications, 1990
- Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging.Proceedings of the National Academy of Sciences, 1990